The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases

Beijian Zhang; Hao Jiang; Zhen Dong; Aijun Sun; Junbo Ge

doi:10.1016/j.gendis.2020.07.011

您当前的位置：

首页 >

文章列表页 >

The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases

Review article | 更新时间：2022-06-24

- The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases
- The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases
- Genes & Diseases 2021年8卷第6期
- 作者机构：
  
  1. Department of Cardiology, Zhongshan Hospital, Fudan University,Shanghai,PR China,200032
  2. Shanghai Institute of Cardiovascular Diseases,Shanghai,PR China,200003
  3. NHC Key Laboratory of Viral Heart Diseases,Shanghai,PR China,200032
  4. Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences,Shanghai,PR China,200032
  5. Institutes of Biomedical Sciences, Fudan University,Shanghai,PR China,200433
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.07.011
  中图分类号：
- 纸质出版日期：2021，
  
  网络出版日期：2021-11-1，
扫描看全文
Beijian Zhang, Hao Jiang, Zhen Dong, 等. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases[J]. Genes & Diseases, 2021,8(6).

Beijian Zhang, Hao Jiang, Zhen Dong, et al. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases[J]. Genes & Diseases, 2021,8(6).
Beijian Zhang, Hao Jiang, Zhen Dong, 等. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases[J]. Genes & Diseases, 2021,8(6). DOI： 10.1016/j.gendis.2020.07.011.

Beijian Zhang, Hao Jiang, Zhen Dong, et al. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases[J]. Genes & Diseases, 2021,8(6). DOI： 10.1016/j.gendis.2020.07.011.

摘要

Abstract

N6-methyladenosine (m6A) RNA methylation is an emerging area of epigenetics

which is a reversible and dynamic modification mediating by ‘writers’ (methylase

adding methyl groups

METTL3

METTL14

and WTAP)

‘erasers’ (demethylase

deleting methyl groups

FTO and ALKBH5)

and ‘readers’ (YTHDF1-3

YTHDC1 and YTHDC2). Recent studies in human

animal models and cell levels have disclosed a critical role of m6A modification in regulating the homeostasis of metabolic processes and cardiovascular function. Evidence from these studies identify m6A as a candidate of biomarker and therapeutic target for metabolic abnormality and cardiovascular diseases (CVD). Comprehensive understanding of the complexity of m6A regulation in metabolic diseases and CVD will be helpful for us to understand the pathogenesis of CVD. In this review

we discuss the regulatory role of m6A in metabolic abnormality and CVD. We will emphasize the clinical relevance of m6A dysregulation in CVD.

关键词

Keywords

Cardiovascular diseaseFTOHeart failureMetabolic syndromeMETTL3Myocardial infarctionN6-methyladenosineRNA epigenetics

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases

Liver-specific Mettl3 ablation delays liver regeneration in mice

Cardiac regeneration: Pre-existing cardiomyocyte as the hub of novel signaling pathway

RNA m⁶A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression

Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets